Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients.

Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients.

<h4>Background</h4>Flubendazole, originally developed to treat infections with intestinal nematodes, has been shown to be efficacious in animal models of filarial infections. For treatment of filarial nematodes, systemic exposure is needed. For this purpose, an orally bioavailable amorph...

Full description

Bibliographic Details
Main Authors: Sophie Lachau-Durand, Lieve Lammens, Bas-Jan van der Leede, Jacky Van Gompel, Graham Bailey, Marc Engelen, Ann Lampo
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS Neglected Tropical Diseases
Online Access:https://doi.org/10.1371/journal.pntd.0007026

Similar Items

Similar Items